Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000625 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 2,100
- Enrollment target
NCT00000625: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000625 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,100 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1479% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000625, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,100 participants
- Enrollment target
Study Summary
To determine the efficacy and safety of zidovudine ( AZT ) versus didanosine ( ddI ), AZT plus ddI, and AZT plus zalcitabine ( ddC ) in preventing disease progression in HIV-infected patients with CD4 counts of 200-500 cells/mm3.
Interventions
- DRUG Zidovudine
- DRUG Didanosine
- DRUG Zalcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,100 participants |
| Est. Completion | 1995-11 |
| Phase | Phase 2 |
What the finished NCT00000625 record still lists
NCT00000625 is an interventional study that assigns participants to a tested intervention. Its 2,100 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1479% higher).
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00000625 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000625 about?
NCT00000625 is a clinical study titled "A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3". To determine the efficacy and safety of zidovudine ( AZT ) versus didanosine ( ddI ), AZT plus ddI, and AZT plus zalcitabine ( ddC ) in preventing disease progression in HIV-infected patients with CD4 counts of 200-500 cells/mm3.
What is the current status of trial NCT00000625?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,100 participants. Estimated completion is 1995-11.
What interventions are being tested in trial NCT00000625?
The interventions under investigation include: Zidovudine (DRUG), Didanosine (DRUG), Zalcitabine (DRUG).
Who is sponsoring clinical trial NCT00000625?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00000625's enrollment target sits among peer trials
2,100 8th of 2000 higher than 1,993 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
- NCT06324981 · 2,100 participants · NA
Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors